Dextromethorphan and high-dose benzoate therapy for nonketotic hyperglycinemia in an infant

Ada Hamosh, John W. McDonald, David Valle, Clair A. Francomano, Ernst Niedermeyer, Michael V. Johnston

Research output: Contribution to journalArticlepeer-review

Abstract

To test the hypothesis that nonketotic hyperglycinemia causes overstimulation of the excitatory N-methyl-d-aspartate receptor by allosteric glycine activation, and that reduction of glycine and blocking of the cation channel coupled to the receptor would be beneficial, we administered benzoate and dextromethorphan, a blocker of the N-methyl-d-aspartate channel to an infant with nonketotic hyperglycinemia. Therapy with benzoate, 500 mg/kg per day, was started on day 5, and the dosage was increased to 750 mg/kg per day on day 8, with prompt normalization of the neurologic and electroencephalographic findings. The glycine concentrations in both plasma and cerebrospinal fluid were substantially reduced. Dextromethorphan was added to the regimen on day 12. The electroencephalogram remained normal until the infant was 8 months of age, when diffuse slowing became apparent. Serial brain magnetic resonance imaging showed delayed myelination. At 12 months of age, physical examination findings and growth were normal except for hypotonia. The developmental quotient was approximately 60, and the child was free of seizures. This outcome, although not ideal, is better than that typical for nonketotic hyperglycinemia. Our results suggest that trials with additional patients and other N-methyl-d-aspartate cation channel blockers are warranted.

Original languageEnglish (US)
Pages (from-to)131-135
Number of pages5
JournalThe Journal of pediatrics
Volume121
Issue number1
DOIs
StatePublished - Jul 1992

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Dextromethorphan and high-dose benzoate therapy for nonketotic hyperglycinemia in an infant'. Together they form a unique fingerprint.

Cite this